Aclaris Therapeutics, Inc.
ACRS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $25 | $25 | $30 | $25 |
| Short-Term Investments | $71 | $74 | $75 | $89 |
| Receivables | $5 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $0 | $4 | $3 | $12 |
| Total Curr. Assets | $101 | $104 | $109 | $126 |
| Property Plant & Equip (Net) | $3 | $1 | $1 | $1 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $71 | $81 | $85 | $90 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $3 | $3 | $3 |
| Total NC Assets | $75 | $85 | $89 | $94 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $176 | $189 | $198 | $220 |
| Liabilities | – | – | – | – |
| Payables | $9 | $9 | $6 | $5 |
| Short-Term Debt | $1 | $0 | $0 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $6 | $4 | $4 | $4 |
| Other Curr. Liab. | $10 | $14 | $11 | $23 |
| Total Curr. Liab. | $26 | $27 | $22 | $32 |
| LT Debt | $2 | $0 | $0 | $0 |
| Deferred Rev, NC | $0 | $18 | $19 | $20 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $28 | $12 | $13 | $13 |
| Total NC Liab. | $30 | $31 | $33 | $33 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $2 | $0 | $0 | $0 |
| Total Liabilities | $55 | $57 | $54 | $65 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$948 | -$933 | -$918 | -$903 |
| AOCI | $1 | $0 | $0 | $0 |
| Other Equity | $1,067 | $1,065 | $1,062 | $1,058 |
| Total Equity | $120 | $132 | $144 | $156 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $176 | $189 | $198 | $220 |
| Net Debt | -$23 | -$25 | -$30 | -$25 |